JP2020532547A5 - - Google Patents

Download PDF

Info

Publication number
JP2020532547A5
JP2020532547A5 JP2020512612A JP2020512612A JP2020532547A5 JP 2020532547 A5 JP2020532547 A5 JP 2020532547A5 JP 2020512612 A JP2020512612 A JP 2020512612A JP 2020512612 A JP2020512612 A JP 2020512612A JP 2020532547 A5 JP2020532547 A5 JP 2020532547A5
Authority
JP
Japan
Prior art keywords
acceptable salt
compound according
drug
drug biological
biological acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020512612A
Other languages
English (en)
Japanese (ja)
Other versions
JP7177825B2 (ja
JP2020532547A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/048388 external-priority patent/WO2019046330A1/en
Publication of JP2020532547A publication Critical patent/JP2020532547A/ja
Publication of JP2020532547A5 publication Critical patent/JP2020532547A5/ja
Application granted granted Critical
Publication of JP7177825B2 publication Critical patent/JP7177825B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020512612A 2017-08-29 2018-08-28 スピロ環化合物並びにその作製及び使用方法 Active JP7177825B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762551714P 2017-08-29 2017-08-29
US62/551,714 2017-08-29
PCT/US2018/048388 WO2019046330A1 (en) 2017-08-29 2018-08-28 SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF

Publications (3)

Publication Number Publication Date
JP2020532547A JP2020532547A (ja) 2020-11-12
JP2020532547A5 true JP2020532547A5 (enExample) 2021-10-07
JP7177825B2 JP7177825B2 (ja) 2022-11-24

Family

ID=65526036

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020512612A Active JP7177825B2 (ja) 2017-08-29 2018-08-28 スピロ環化合物並びにその作製及び使用方法

Country Status (24)

Country Link
US (1) US11161856B2 (enExample)
EP (1) EP3675848B1 (enExample)
JP (1) JP7177825B2 (enExample)
KR (1) KR20200046053A (enExample)
CN (1) CN111032034B (enExample)
AU (1) AU2018326497A1 (enExample)
BR (1) BR112020003946A2 (enExample)
CA (1) CA3072926A1 (enExample)
CL (1) CL2020000463A1 (enExample)
CO (1) CO2020001715A2 (enExample)
CR (1) CR20200088A (enExample)
DO (1) DOP2020000040A (enExample)
EA (1) EA202090296A1 (enExample)
EC (1) ECSP20013332A (enExample)
ES (1) ES2914363T3 (enExample)
IL (1) IL272578A (enExample)
JO (1) JOP20200022A1 (enExample)
MA (1) MA50045A (enExample)
MX (1) MX2020002254A (enExample)
PE (1) PE20200665A1 (enExample)
PH (1) PH12020500371A1 (enExample)
RU (1) RU2020107039A (enExample)
SG (1) SG11202000984YA (enExample)
WO (1) WO2019046330A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX350788B (es) 2012-01-06 2017-09-13 Abide Therapeutics Inc Compuestos de carbamato y preparación y uso de los mismos.
WO2017197192A1 (en) 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
CN109996790B (zh) 2016-09-19 2023-05-16 H.隆德贝克有限公司 哌嗪氨基甲酸酯及其制备和使用方法
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
UA126685C2 (uk) 2017-08-29 2023-01-11 Луннбек Ла-Холья Рісьоч Сенте, Інк. Сполуки, які є модуляторами magl, і способи їх отримання і застосування
JP7177825B2 (ja) 2017-08-29 2022-11-24 ハー・ルンドベック・アクチエゼルスカベット スピロ環化合物並びにその作製及び使用方法
EP3793547A4 (en) 2018-05-15 2021-11-17 H. Lundbeck A/S MAGL INHIBITORS
CN111505410B (zh) * 2020-04-02 2022-07-29 矽力杰半导体技术(杭州)有限公司 调光模式检测电路、方法和无调光检测电路及照明系统
AU2021259496A1 (en) 2020-04-21 2022-11-10 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
TWI904281B (zh) 2020-11-13 2025-11-11 丹麥商H 朗德貝克公司 Magl抑制劑
WO2022165513A1 (en) 2021-01-29 2022-08-04 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
CA3225439A1 (en) 2021-06-26 2022-12-29 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
IL313987A (en) 2021-12-29 2024-08-01 Psy Therapeutics Inc Inhibiting monoacylglycerol lipase (magl)
IL316302A (en) 2022-05-04 2024-12-01 H Lundbeck As Crystalline form of 111333-hexafluoropro s-1-pyridazin-3-ylca azaspiro2.5octane-6- as a monoacylglycerol lipase inhibitor
WO2024168426A1 (en) 2023-02-13 2024-08-22 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03008109A (es) 2001-03-07 2003-12-12 Pfizer Prod Inc Moduladores de la actividad de receptores de quimiocinas.
WO2008023720A1 (en) * 2006-08-23 2008-02-28 Astellas Pharma Inc. Urea compound or salt thereof
US20110071180A1 (en) 2008-03-05 2011-03-24 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
ES2585806T3 (es) 2009-10-23 2016-10-10 Janssen Pharmaceutica N.V. Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina
AU2011223898A1 (en) 2010-03-04 2012-09-13 Merck Sharp & Dohme Corp. Positive allosteric modulators of mGluR2
FR2960875B1 (fr) * 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
MX350788B (es) * 2012-01-06 2017-09-13 Abide Therapeutics Inc Compuestos de carbamato y preparación y uso de los mismos.
EP3590940B1 (en) 2012-09-25 2021-06-09 F. Hoffmann-La Roche AG Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases
MX2015017961A (es) 2013-07-03 2016-10-14 Abide Therapeutics Inc Compuestos orgánicos pirrolo-pirrol carbamato y relacionados, composiciones farmacéuticas y usos médicos de los mismos.
WO2016149401A2 (en) 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
HK1249101A1 (zh) 2015-07-31 2018-10-26 辉瑞公司 作为magl抑制剂的1,1,1-三氟-3-羟基丙-2-基氨基甲酸酯衍生物及1,1,1-三氟-4-羟基丁-2-基氨基甲酸酯衍生物
EP3377060B1 (en) 2015-11-20 2020-08-19 Lundbeck La Jolla Research Center, Inc. Pyrazole derivatives, processes for their preparation and uses thereof
WO2017197192A1 (en) 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
UA126685C2 (uk) 2017-08-29 2023-01-11 Луннбек Ла-Холья Рісьоч Сенте, Інк. Сполуки, які є модуляторами magl, і способи їх отримання і застосування
JP7177825B2 (ja) 2017-08-29 2022-11-24 ハー・ルンドベック・アクチエゼルスカベット スピロ環化合物並びにその作製及び使用方法

Similar Documents

Publication Publication Date Title
JP2020529994A5 (enExample)
JP2020532545A5 (enExample)
JP2014511891A5 (enExample)
JP2019524883A5 (enExample)
JP2017523225A5 (enExample)
JP2015508103A5 (enExample)
JP2016530259A5 (enExample)
JP2019034943A5 (enExample)
JP2017528503A5 (enExample)
JP2019509276A5 (enExample)
JP2009531403A5 (enExample)
JP2020502047A5 (enExample)
JP2019526596A5 (enExample)
JP2020507589A5 (enExample)
JP2017531038A5 (enExample)
JP2018536634A5 (enExample)
JP2019531279A5 (enExample)
JP2017520613A5 (enExample)
JP2017526674A5 (enExample)
JP2018529650A5 (enExample)
JP2007502295A5 (enExample)
JP2019516739A5 (enExample)
JP2017531619A5 (enExample)
JP2019510027A5 (enExample)
JP2016522254A5 (enExample)